Study Groups

Three topics have been identified to launch those study groups. Each topic will be deliverable within a maximum of two years.

The nucleus has also nominated three theme coordinators to administer this new structure (see figure below). They will be responsible for the oversight of the study groups and liaison between the study groups and the nucleus. 
Theme coordinators are appointed for two years.

Structure 

•  Study Group on Genetic cardiomyopathies
  Coordinator: Jens Mogensen
  Topic: Development of a joint advisory group with specialist genetic societies/working groups

• Study Group on Inflammatory and infective heart muscle disease
  Coordinator: Alida Caforio
  Topic: Development of supporting documentation for a possible future position statement on the diagnosis and treatment of myocarditis

• Study Group on Pericardial diseases/interventional pericardiology
  Coordinator: Arsen Ristic
  Topic: Development of an advisory group on current clinical need and available procedures on interventional pericardiology

Role of Study Groups leaders:

Each study group will work in partnership with their theme coordinator from the nucleus.

Each study group leader will serve for one year, with the possibility of extension for one additional year.

In consultation with their theme coordinator, each study group leader may nominate up to six individuals (the “study group”) to assist them in the delivery of their allocated topic. These individuals do not necessarily need to be Working Group members but must have appropriate skills and knowledge relevant to the study group topic.
The nucleus also aims to encourage the involvement of young investigators as well as more established experts. Membership of the study groups will be scrutinised and approved by the nucleus.

Each study group leader will be expected to produce a report and will have the opportunity to report their group’s progress at the Annual General Meeting.

Appointment of study group leaders:

Study group leaders MUST fulfil the following criteria:

• Membership of the Working Group 
• Demonstrable track record (clinical and/or scientific) in the specific topic
• Ideally not from same institution as an existing nucleus member

All Working Group members are invited to submit their candidacy before May 20th using a web-based standard submission form.

Applications for study group leaders will be assessed by the full nucleus and the successful candidates will be announced within three weeks of the closing date.

Only one individual can be selected for each study group lead.

Candidates not selected for leadership can still be considered as members of each study group if they meet criteria set by the nucleus.

In addition to the three topics selected, we would like to receive your ideas for future topics. You can send your suggestions to the Vice-Chairman of the Working Group, Dr Philippe Charron.